Tarlatamab-Imdelltra clinical trial recruitment information and research progress

Tarlatamab (brand name Imdelltra) is a bispecific T that targets DLL3 (delta-like ligand 3 ) Cell engaging agents are mainly used to treat advanced small cell lung cancer (SCLC). It activates T cells and targets DLL3 high-expressing tumor cells to achieve specific killing of tumor cells. It is especially suitable for patients with extensive stage SCLC of disease progression after platinum-based chemotherapy.

In clinical studies, the II phase DeLLphi-301 trial shows that Tarlatamab is effective in multi-line treatment SCLC It has significant efficacy in patients, with an objective response rate (ORR) of about 40% and a median duration of response (DOR) of about 9.7 months. Phase III DeLLphi-304 Interim results showed that the median overall survival (OS) reached 13.6 months, compared with 8.3 in the standard chemotherapy group. months were significantly improved, and progression-free survival (PFS) was also prolonged, suggesting its potential in extending survival and controlling the disease.

Currently, clinical trials of Tarlatamab are still ongoing, including DeLLphi-304 Phase III randomized controlled trial and I/II A period of research exploring combined treatment strategies. The patients recruited were mainly adults with extensive-stage SCLC after progression on platinum-based chemotherapy, with ECOG score 0-1 and measurable lesions. Some early studies also observed certain activity against brain metastases, providing reference for future research.

Future research will focus on the potential of combination immunotherapy, chemotherapy or other targeted therapies, as well as the assessment of long-term safety and resistance mechanisms. Patients taking Tarlatamab need to be aware of potential side effects, such as cytokine release syndrome and neurotoxicity, and be treated at an experienced center. Overall, Tarlatamab represents a new direction in the treatment of small cell lung cancer, and its clinical research and recruitment information provide new hope for advanced patients.

Reference materials:https://www.drugs.com/